Riskpilot← Back to searchSign inGet full accessSOLika swe AB
ABActiveOrg 5569786105Tollerud 130Manufacture of pharmaceutical preparations · NACE 2120Est. 20140 employees
Revenue 2025
SEK 148K
+327% vs 2024
EBITDA margin
90.2%
+387% vs 2024
Equity ratio
89.5%
Financial strength
Net profit 2025
SEK 106K
+400% vs 2024
| Revenue | SEK 148K | +327% |
| EBITDA | SEK 134K | +387% |
| Net profit | SEK 106K | +400% |
| Total assets | SEK 271K | +73% |
| Equity | SEK 243K | +77% |
| Employees | 0 | — |
Legal name
SOLika swe AB
Org number
5569786105
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1 augusti 2014
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva handelmed/och utveckling av läkemedel och medicinsk teknik samt undervisning.
Address
Tollerud 130
Email
lotta.langer@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 11 | 127 | 85 | 35 | 148 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 7 | 122 | 78 | 27 | 134 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 7 | 122 | 78 | 27 | 134 |
| Net financials | — | — | — | −1 | −1 |
| Profit before tax | 6 | 122 | 77 | 27 | 133 |
| Tax | −1 | −25 | −16 | −6 | −28 |
| Net profit | 5 | 97 | 61 | 21 | 106 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 63 | 197 | 289 | 157 | 271 |
| Equity | 58 | 155 | 216 | 137 | 243 |
| Long-term debt | 2 | 2 | 2 | 2 | 2 |
| Short-term debt | 3 | 40 | 71 | 17 | 26 |
| Total debt | 5 | 42 | 73 | 19 | 28 |
EBITDA margin
90.2%
This company
15.8%
Market median
+471% vs market
20212025
Equity ratio
89.5%
This company
38.2%
Market median
+134% vs market
20212025
Return on equity
43.4%
This company
18.4%
Market median
+136% vs market
20212025
Net profit margin
71.2%
This company
8.1%
Market median
+779% vs market
20212025
Asset turnover
0.55×
This company
1.12×
Market median
-51% vs market
20212025
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-09-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SOLika swe AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dan Wiking Stefan Willmarsson | Board of Directors | 0 companies |
| Sven Thomas Langer | Deputy Board Member | 0 companies |
| Anna Charlotta Langer | Chairman | 0 companies |
| Eva Charlotta Ljungberg | Deputy Board Member | 0 companies |